Penile Traction Device for Small Penis: What the Evidence Supports for Short-Penis and Micropenis Cohorts

That answer holds two truths at once. For the large majority of men in this query — those with a self-perceived small penis, or a measured length below their personal or cultural average but still within the statistical normal range — calibrated traction is a legitimate, evidence-supported option for modest cosmetic gain. The expected change is real but measured in roughly a centimetre to two and a half, not in inches of marketing copy. For the smaller group with clinically diagnosed micropenis, the honest answer is different: traction may still have a role, but only after a urologist has assessed the underlying cause. The published gains above describe short-penis cohorts; for a fuller picture of how consistently traction performs across all trials, see do penis extenders really work.

Two different situations sit behind the phrase “small penis,” and they are not interchangeable. One is a common variation within normal anatomy; the other is a formal medical diagnosis. Telling them apart determines whether your sensible first step is a traction protocol or a urology appointment.

The distinction matters because clinical micropenis requires urology and endocrine evaluation — testing that may include testosterone and growth-hormone assessment — before any traction protocol begins. The underlying cause may have a primary treatment that traction alone will not address, and starting a device without that assessment can delay appropriate care. Consult your healthcare provider for a stretched-penile-length measurement and clinical assessment before assuming a small penis is, or is not, micropenis.

Four peer-reviewed studies anchor what calibrated medical traction can realistically achieve for the short-penis cohort. Each measured length gain on a calibrated device, and together they describe modest, sustained outcomes — the basis for the mechanism explained in how a penile traction device works.

1. Levine & Rybak 2011, PMID: 21492409, pre-prosthesis short-penis cohort. Levine and Rybak applied calibrated traction for 2–4 hours per day across 2–4 months in men with a shortened penis prior to penile prosthesis implantation, and reported up to +1.5 cm (about 0.6 inch) erect length gain in 70% of subjects, with no adverse events recorded.
2. Almsaoud 2023 pooled meta-analysis (PMID: 36895692). The Almsaoud 2023 meta-analysis pooled multiple traction-therapy trials and calculated a 1.9 cm pooled mean length gain (Almsaoud 2023, PMID: 36895692) — roughly 0.75 inch — alongside an approximately 11–14% rate of mild, transient adverse events.
3. Gontero 2009, PMID: 19138361. Gontero and colleagues measured a +1.3 cm (about 0.5 inch) mean flaccid length gain across 15 men using calibrated medical traction at 4–6 hours per day across 6 months.
4. Nikoobakht 2011, PMID: 20102448. Nikoobakht and colleagues, studying 23 men with a shortened penis, reported a +1.7 cm (about 0.7 inch) mean flaccid length gain on calibrated traction over a 3-month protocol.

Read together, this literature supports a consistent conclusion: calibrated medical traction produces modest, sustained length gain in the short-penis cohort. It does not support dramatic transformation. For the complete evidence base see do penis extenders really work, and for documented outcomes over time see penis extender results: before and after.

Setting expectations correctly is the difference between a satisfied user and a disappointed one. The clinical evidence points to a specific, modest range — and matching your expectations to that range from the start is itself a predictor of satisfaction.

• Length gain. Expect roughly 1.0–2.5 cm (0.4–1.0 inch) of flaccid length gain, with a 1.9 cm pooled mean length gain (Almsaoud 2023, PMID: 36895692) as the central estimate. Expecting “+3 inches” reflects marketing, not clinical data, and reliably produces disappointment.
• Timeline. A first measurable signal typically appears around weeks 8–12, with results tending to plateau by months 4–6. The detailed month-by-month picture is set out in penis extender results: before and after.
• Compliance. Consistent wear of 4–6 hours per day is the strongest single predictor of outcome — completers gain more than non-completers. The daily routine that supports this is covered in how to use a penile traction device.
• Individual variation. Some users gain more than the pooled mean and some gain less. A pooled mean is an average across cohorts, not a guarantee for any one person. Length is also a separate goal from girth — if girth matters to you, see penile traction device for girth.

For the clinically diagnosed micropenis cohort, traction outcomes are far less studied, and published figures above should not be assumed to transfer. If that may describe you, consult your healthcare provider before forming any expectation at all.

Calibrated traction can be a reasonable starting point for the short-penis cohort, but five specific situations should send you to a urologist first. Each one signals that a clinical assessment belongs ahead of any device.

1. Stretched penile length below 7.5 cm. An SPL below roughly 7.5 cm (3.0 inches) suggests possible clinical micropenis and warrants a formal measurement and assessment.
2. A history of hormonal abnormality. Low testosterone, delayed puberty, or other endocrine concerns can underlie reduced penile length and may need primary treatment.
3. Erectile dysfunction or other sexual-function concerns. Difficulty with erections alongside size concerns deserves clinical evaluation in its own right.
4. Existing Peyronie's disease or penile curvature. Curvature is a different cohort with a different protocol — see penile traction device for Peyronie's disease — and should be assessed before starting general traction.
5. Significant body dysmorphia or size-related anxiety. Marked distress about penile size — sometimes diagnosed as penile dysmorphic disorder (PDD) — often benefits from psychological evaluation alongside any physical intervention.

None of this rules traction out. For clinical cases, traction can still be part of a broader treatment plan — but urology is the first step, and a device is not a substitute for a diagnosis.

SizeGenetics is one of the calibrated medical traction devices represented in the meta-analytic literature, including the pooled trials behind Almsaoud 2023. It is an FDA-registered Class II medical device, manufactured in Lyngby, Denmark since 1995, and was co-invented by Dr. Jørn Ege Siana, board-certified plastic surgeon. FDA registration is a manufacturer-and-device listing process and is not the same as FDA approval — see what that FDA-registered Class II medical device classification involves.

The SizeGenetics line is offered in several editions that differ mainly in their bundled comfort accessories rather than in the calibrated traction itself. For a first-time user in the short-penis cohort, an edition with a fuller set of comfort accessories is often the practical choice, because comfort support sustains the 4–6 hours of daily wear that the evidence ties to better outcomes. Full product detail and the current editions sit on the SizeGenetics medical traction device page; to compare editions against price, see the penile traction device buy guide and the criteria for the best penile traction device. For how a regulated device delivers therapy in the first place, see penile traction device: how medical devices deliver therapy.

Co-Inventor of SizeGenetics

Dr. Jørn Ege Siana, M.D.

SizeGenetics was co-invented by Dr. Jørn Ege Siana, board-certified plastic surgeon. His clinical background shaped the device as a regulated medical instrument from its origin, intended for calibrated, well-tolerated traction rather than improvised stretching.

• Board-certified plastic surgeon
• Co-inventor of the SizeGenetics penile traction device
• Medical advisor (legacy), Copenhagen

Calibrated traction for the short-penis cohort connects to a wider cluster of device-education and evidence pages. Each page below answers the logical next question for a reader weighing the option.